Fortress Biotech Inc Pref Series A (FBIOP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $77.81M
Last updated: Nov 17, 2026 at 10:47 AM ET
Fortress Biotech Inc Pref Series A (FBIOP) Financials: Revenue, Profit and Cash Flow
Fortress Biotech Inc Pref Series A reported revenue of $63.26M for the fiscal year ended Dec 31, 2025, up 9.7% from the year before. That year, net income was $6.82M with a net margin of 10.8%, operating cash flow was -$65.78M and free cash flow was -$65.78M. The quarter ended Sep 30, 2026 had revenue of $19.16M and net income of -$5.84M.
Revenue and Margins
The net margin was 10.8% in the fiscal year ended Dec 2025, the highest of the 5 years shown with a net margin. Over the 9 years to Dec 2025, revenue grew from $16.48M, a compound annual rate of 16.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $63.26M | +9.7% | 66.9% | -111.0% | 10.8% |
| Dec 2024 | $57.67M | -31.8% | 63.8% | -191.4% | -79.8% |
| Dec 2023 | $84.51M | +11.6% | 72.9% | -168.4% | -71.7% |
| Dec 2022 | $75.74M | +10.1% | 59.4% | -268.8% | -114.3% |
| Dec 2021 | $68.79M | +50.9% | 53.4% | -274.1% | -94.1% |
| Dec 2020 | $45.60M | +24.5% | 68.0% | -206.7% | -102.0% |
| Dec 2019 | $36.63M | +36.3% | 71.2% | -302.5% | -109.1% |
| Dec 2018 | $26.88M | -85.7% | 77.2% | -446.4% | -313.0% |
| Dec 2017 | $187.58M | +1038.3% | 14.1% | -47.9% | -35.7% |
| Dec 2016 | $16.48M | N/A | 31.1% | -398.7% | -334.3% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63.26M | $57.67M | $84.51M | $75.74M | $68.79M | $45.60M | $36.63M | $26.88M | $187.58M | $16.48M |
| Cost of revenue | $20.92M | $20.88M | $22.89M | $30.77M | $32.08M | $14.59M | $10.53M | $6.13M | $161.20M | $11.35M |
| Gross profit | $42.34M | $36.80M | $61.62M | $44.97M | $36.71M | $31.00M | $26.10M | $20.76M | $26.38M | $5.13M |
| Research and development | $11.90M | $56.88M | $106.07M | $134.88M | $128.87M | $64.11M | $81.33M | $87.38M | $52.49M | $35.13M |
| Operating income | -$70.22M | -$110.38M | -$142.34M | -$203.56M | -$188.54M | -$94.27M | -$110.82M | -$120.00M | -$89.80M | -$65.71M |
| Net income | $6.82M | -$46.00M | -$60.64M | -$86.58M | -$64.70M | -$46.53M | -$39.96M | -$84.15M | -$66.88M | -$55.09M |
| EBITDA | -$20.16M | -$104.49M | -$135.72M | -$193.69M | -$146.17M | -$87.82M | -$88.48M | -$118.40M | -$88.57M | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.16M | $18.72M | $16.04M | $16.08M | $17.63M | $16.41M | $13.14M | $15.12M | $14.63M | $14.90M | $13.03M | $19.95M |
| Gross profit | $13.28M | $11.61M | $8.69M | $10.64M | $11.88M | $11.47M | $8.35M | $9.31M | $9.34M | $8.36M | $7.03M | $13.93M |
| Operating income | -$7.19M | -$10.01M | -$7.74M | -$4.79M | -$6.81M | -$36.47M | -$22.32M | -$27.34M | -$22.09M | -$27.79M | -$36.57M | -$19.61M |
| Net income | -$5.84M | -$468.00K | $110.37M | -$3.94M | $5.85M | $15.49M | -$10.58M | -$6.76M | -$12.87M | -$10.95M | -$15.42M | -$9.28M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $61.63M by $17.75M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $185.55M | $144.22M | $167.53M | $294.30M | $396.50M | $333.41M | $226.42M | $140.99M | $245.95M | $170.73M |
| Current assets | $123.84M | $90.37M | $117.02M | $230.43M | $346.46M | $266.15M | $156.25M | $111.21M | $183.18M | $109.63M |
| Cash and equivalents | $79.38M | $57.26M | $80.93M | $178.27M | $305.74M | $233.35M | $136.86M | $65.51M | $113.92M | $88.29M |
| Total liabilities | $123.36M | $145.87M | $165.94M | $244.28M | $170.63M | $136.41M | $153.89M | $121.25M | $125.45M | $87.76M |
| Short-term debt | $2.13M | $3.25M | $5.52M | $12.63M | $7.43M | $6.37M | $9.00M | $19.08M | $13.23M | $2.03M |
| Long-term debt | $59.50M | $57.96M | $60.86M | $93.14M | $46.56M | $59.04M | $82.43M | $60.42M | $53.28M | $26.18M |
| Shareholder equity | $49.87M | $22.74M | $22.54M | $41.72M | $108.67M | $100.34M | $26.21M | $1.85M | $52.57M | $38.49M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $280.21M | $316.71M | $356.87M | $185.55M | $181.41M | $159.90M | $178.07M | $144.22M | $127.08M | $145.69M | $164.65M | $167.53M |
| Total liabilities | $103.19M | $110.63M | $154.50M | $123.36M | $116.22M | $122.51M | $145.59M | $145.87M | $139.82M | $160.28M | $168.58M | $165.94M |
| Cash and equivalents | $152.19M | $196.58M | $255.84M | $79.38M | $86.22M | $74.39M | $91.34M | $57.26M | $58.85M | $76.20M | $85.84M | $80.93M |
| Shareholder equity | $160.00M | $164.14M | $162.21M | $49.87M | $55.86M | $43.92M | $22.25M | $22.74M | $21.16M | $17.88M | $23.02M | $22.54M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$65.78M | -$80.19M | -$128.22M | -$179.40M | -$116.54M | -$83.68M | -$94.96M | -$98.85M | -$85.43M | -$45.81M |
| Capital expenditures | $0 | $15.00M | $8.10M | $3.06M | $16.35M | $7.16M | $9.39M | $9.36M | $5.45M | $10.51M |
| Free cash flow | -$65.78M | -$95.19M | -$136.32M | -$182.46M | -$132.89M | -$90.85M | -$104.36M | -$108.20M | -$90.88M | -$56.32M |
| Dividends paid | $664.00K | $4.71M | $8.77M | $8.78M | $8.78M | $6.75M | $2.56M | $2.34M | $299.00K | $299.00K |
| Investing cash flow | $10.12M | -$15.00M | -$2.10M | -$22.93M | $40.51M | -$7.16M | $20.10M | $18.82M | -$41.63M | -$6.06M |
| Financing cash flow | $77.44M | $70.64M | $32.74M | $75.32M | $148.99M | $172.41M | $146.71M | $50.65M | $150.38M | $42.91M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.20M | -$59.28M | $203.85M | -$12.54M | -$6.11M | -$27.56M | -$19.56M | -$12.91M | -$20.06M | -$21.84M | -$25.39M | -$34.94M |
| Capital expenditures | $7.00K | $79.00K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $63.00K |
| Free cash flow | -$6.20M | -$59.36M | $203.85M | -$12.54M | -$6.11M | -$27.56M | -$19.56M | -$12.91M | -$20.06M | -$21.84M | -$25.39M | -$35.00M |
Frequently Asked Questions About FBIOP
What is Fortress Biotech Inc Pref Series A's annual revenue?
Fortress Biotech Inc Pref Series A reported revenue of $63.26M for the fiscal year ended Dec 31, 2025.
How fast is Fortress Biotech Inc Pref Series A's revenue growing?
Revenue was up 9.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -5.8%.
Is Fortress Biotech Inc Pref Series A profitable?
Yes. Fortress Biotech Inc Pref Series A reported net income of $6.82M for the fiscal year ended Dec 31, 2025, with a net margin of 10.8%.
How much free cash flow does FBIOP generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$65.78M minus capital expenditures of $0 produced free cash flow of -$65.78M.
How much debt does Fortress Biotech Inc Pref Series A have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $59.50M, short-term debt of $2.13M and cash and equivalents of $79.38M.
FBIOP pages: Overview, Financials